Blueprint Medicines Corp (BPMC)
107.88
-0.64
(-0.59%)
USD |
NASDAQ |
Jun 28, 16:00
107.88
0.00 (0.00%)
After-Hours: 20:00
Blueprint Medicines Research and Development Expense (Annual): 427.72M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 427.72M |
| December 31, 2022 | 477.42M |
| December 31, 2021 | 601.03M |
| December 31, 2020 | 326.86M |
| December 31, 2019 | 331.45M |
| December 31, 2018 | 243.62M |
| Date | Value |
|---|---|
| December 31, 2017 | 144.69M |
| December 31, 2016 | 81.13M |
| December 31, 2015 | 48.59M |
| December 31, 2014 | 31.84M |
| December 31, 2013 | 15.93M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
326.86M
Minimum
2020
601.03M
Maximum
2021
432.90M
Average
427.72M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Ligand Pharmaceuticals Inc | 24.54M |
| Biomarin Pharmaceutical Inc | 746.77M |
| Eli Lilly and Co | 9.313B |
| Apellis Pharmaceuticals Inc | 354.39M |
| Arcellx Inc | 133.85M |